Beta Bionics (NASDAQ:BBNX) Announces Quarterly Earnings Results

Beta Bionics (NASDAQ:BBNX) released its quarterly earnings data on Wednesday. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09, FiscalAI reports. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The firm had revenue of $32.01 million for the quarter.

Here are the key takeaways from Beta Bionics’ conference call:

• Q2 revenue increased 38% year over year to $32 million, driven by new patient starts and recurring pharmacy-supply revenue, while gross margin expanded 524 basis points to 59%.
• Management reiterated 2026 revenue guidance of $131 million–$136 million and raised its full-year gross-margin outlook to 58.5%–59.5%, citing pharmacy growth and manufacturing scale.
• The company expects new sales territories added in the first half to support stronger patient-start growth in the second half, with Q3 expected to exceed Q2 and seasonally stronger Q4 performance.
• Beta Bionics is targeting a full commercial launch of the Mint patch pump by the end of Q2 2027, has begun operating a semi-automated clean-room production line, and initiated a pivotal trial to expand iLet use to adults with Type 2 diabetes around mid-2027, subject to FDA clearance.
• The bi-hormonal system requires additional work on glucagon formulation and dosing algorithms, delaying further Phase IIa trials by less than a year; the company also continues remediation of an FDA warning letter focused on complaints handling and post-market surveillance.

Beta Bionics Price Performance

Shares of BBNX stock opened at $15.17 on Thursday. The firm has a 50-day moving average of $14.89 and a 200-day moving average of $13.26. The company has a market cap of $675.98 million, a P/E ratio of -10.05 and a beta of 3.04. Beta Bionics has a one year low of $8.80 and a one year high of $32.71.

Insider Activity at Beta Bionics

In related news, insider Mark Hopman sold 5,329 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total transaction of $67,198.69. Following the transaction, the insider directly owned 130,887 shares in the company, valued at approximately $1,650,485.07. The trade was a 3.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Jon Russell sold 4,222 shares of the company’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total transaction of $53,239.42. Following the completion of the sale, the insider directly owned 173,849 shares of the company’s stock, valued at $2,192,235.89. The trade was a 2.37% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 40,351 shares of company stock valued at $553,961 over the last three months. Insiders own 5.30% of the company’s stock.

Hedge Funds Weigh In On Beta Bionics

Hedge funds and other institutional investors have recently modified their holdings of the business. Eventide Asset Management LLC grew its position in Beta Bionics by 0.8% during the fourth quarter. Eventide Asset Management LLC now owns 4,994,728 shares of the company’s stock valued at $152,233,000 after buying an additional 37,476 shares during the period. Soleus Capital Management L.P. grew its holdings in Beta Bionics by 12.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock valued at $55,622,000 after buying an additional 424,817 shares in the last quarter. Vanguard Group Inc. increased its holdings in Beta Bionics by 213.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock worth $44,036,000 after acquiring an additional 1,509,217 shares during the period. Eversept Partners LP increased its holdings in shares of Beta Bionics by 108.6% in the first quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after purchasing an additional 736,576 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in Beta Bionics in the 4th quarter worth about $40,437,000.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. The Goldman Sachs Group boosted their target price on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Leerink Partners dropped their price target on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 22nd. UBS Group started coverage on Beta Bionics in a research note on Tuesday. They set a “buy” rating and a $22.00 price target for the company. Stifel Nicolaus decreased their price objective on Beta Bionics from $22.00 to $20.00 and set a “buy” rating for the company in a report on Wednesday, April 22nd. Finally, Bank of America lowered their price objective on Beta Bionics from $23.00 to $11.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. Seven investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $20.10.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.